While promising, this expensive treatment requiring complex 18-hour brain surgery will remain inaccessible to most patients who need it. The results come from only 29 patients without peer review, and the therapy doesn't cure the disease but merely delays inevitable decline. Gene therapies often carry hefty price tags that healthcare systems struggle to afford.